Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | KYNU | Q16719 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
| ▸ | CDC25B | P30305 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26466090 | 0.85 | ALDH1A1 (0.54) | ALDH1A1MAPK1L3MBTL1SLC6A2SLC6A3 | |
| SCHEMBL6397781 | 0.85 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1SLC6A2SLC6A3 | |
| SCHEMBL535708 | 0.84 | CA12 (0.49) | ALDH1A1MAPK1L3MBTL1KMT2AKYNU | |
| SCHEMBL5849992 | 0.84 | ALDH1A1 (0.53) | ALDH1A1MAPK1L3MBTL1SLC6A2SLC6A3 | |
| SCHEMBL7691405 | 0.84 | ALDH1A1 (0.52) | ALDH1A1MAPK1L3MBTL1KMT2APOLB | |
| SCHEMBL842400 | 0.83 | ALDH1A1 (0.45) | ALDH1A1MAPK1L3MBTL1SLC6A2SLC6A3 | |
| SCHEMBL28378069 | 0.83 | ALDH1A1 (0.59) | ALDH1A1MAPK1L3MBTL1SLC6A2SLC6A3 | |
| SCHEMBL25135085 | 0.82 | ALDH1A1 (0.54) | ALDH1A1MAPK1L3MBTL1SLC6A2SLC6A3 | |
| SCHEMBL9726800 | 0.82 | ALDH1A1 (0.44) | ALDH1A1MAPK1L3MBTL1SLC6A2SLC6A3 | |
| SCHEMBL6169362 | 0.81 | ALDH1A1 (0.61) | ALDH1A1MAPK1L3MBTL1SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4087583-B1 | ARGINASE INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12570662-B2 | Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases | NURIX THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-12421210-B2 | Fused bicyclic heterocycles as therapeutic agents | NEW YORK UNIVERSITY (US) | 2025-09-23 | — | — | US | disclosed |
| EP-4512402-A2 | BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF | Nurix Therapeutics, Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| EP-4367118-B1 | BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF | NURIX THERAPEUTICS INC (US) | 2025-01-29 | — | — | EP | disclosed |
| US-20240417402-A1 | SUBSTITUTED PYRROLO[1,2-b]PYRIDAZINES AS BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES | GILEAD SCIENCES, INC. | 2024-12-19 | — | — | US | disclosed |
| CN-118515685-A | Synthesis of halichondrin | 哈佛大学的校长及成员们 | 2024-08-20 | — | — | CN | disclosed |
| EP-4367118-A1 | BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF | Nurix Therapeutics, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| US-11976071-B2 | Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases | GILEAD SCIENCES, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| CN-111433211-B | Synthesis of halichondrin | 哈佛大学的校长及成员们 | 2024-05-07 | — | — | CN | disclosed |
| US-20080234301-A1 | Alpha-4 Integrin Mediated Cell Adhesion Inhibitors for the Treatment or Prevention of Inflammatory Diseases | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-09-25 | — | — | US | disclosed |
| EP-1778225-A2 | PYRROLO(OXO)ISOQUINOLINES AS 5HT LIGANDS | Bristol-Myers Squibb Company (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1737826-A1 | ALPHA-4 INTEGRIN MEDIATED CELL ADHESION INHIBITORS FOR THE TREATMENT OR PREVENTION OF INFLAMMATORY DISEASES | TANABE SEIYAKU CO., LTD. (JP) | 2007-01-03 | — | — | EP | disclosed |
| WO-2006019886-A2 | PYRROLO(OXO)ISOQUINOLINES AS 5HT LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-23 | — | — | WO | disclosed |
| US-20060014777-A1 | Pyrrolo(oxo)isoquinolines as 5HT ligands | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-19 | — | — | US | disclosed |
| WO-2005075438-A1 | ALPHA-4 INTEGRIN MEDIATED CELL ADHESION INHIBITORS FOR THE TREATMENT OR PREVENTION OF INFLAMMATORY DISEASES | TANABE SEIYAKU CO., LTD. (JP) | 2005-08-18 | — | — | WO | disclosed |
| EP-0214639-B1 | HYDROXAMIC ACID BASED COLLAGENASE INHIBITORS | G.D. Searle & Co. (US) | 1990-06-13 | — | — | EP | disclosed |
| US-4743587-A | ANTIARTHRITIC AGENTS | G. D. SEARLE & CO. (US) | 1988-05-10 | — | — | US | disclosed |
| EP-0214639-A2 | Hydroxamic acid based collagenase inhibitors | G.D. Searle & Co. (US) | 1987-03-18 | — | — | EP | disclosed |
| US-4599361-A | ANTIARTHRITIC | G. D. SEARLE & CO. (US) | 1986-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421210-B2 | Fused bicyclic heterocycles as therapeutic agents | NAMPT, NQO1, NAPRT | ALDH1A1 1562/4885MAPK1 3874/4885L3MBTL1 2762/4885 |
| US-12570662-B2 | Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases | IRAK1, IRAK2, IRAK4 | ALDH1A1 1750/4885MAPK1 235/4885L3MBTL1 3192/4885 |
| US-20080234301-A1 | Alpha-4 Integrin Mediated Cell Adhesion Inhibitors for the Treatment or Prevention of Inflammatory Diseases | ITGB4, ITGA4, ICAM1 | ALDH1A1 431/4885MAPK1 682/4885L3MBTL1 3608/4885 |
| US-20240417402-A1 | SUBSTITUTED PYRROLO[1,2-b]PYRIDAZINES AS BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES | IRAK1, IRAK2, IRAK4 | ALDH1A1 1402/4885MAPK1 181/4885L3MBTL1 1725/4885 |
| US-20060014777-A1 | Pyrrolo(oxo)isoquinolines as 5HT ligands | HTR2B, OPRD1, HTR1B | ALDH1A1 2732/4885MAPK1 2588/4885L3MBTL1 2366/4885 |
| US-11976071-B2 | Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases | IRAK1, IRAK2, IRAK4 | ALDH1A1 1131/4885MAPK1 134/4885L3MBTL1 2675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.